美国获批-话题@MedSci

#美国获批#

18篇内容 | 305人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1807405, encodeId=0322180e405fc, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=阿斯利康和第一三共制药的Enhertu在美国获批用于早期治疗乳腺癌, objectType=article, longId=726473, objectId=c6fee264732d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6fee264732d, replyNumber=0, likeNumber=46, createdTime=2022-10-26, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6fee264732d, moduleTitle=阿斯利康和第一三共制药的Enhertu在美国获批用于早期治疗乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6fee264732d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807404, encodeId=57d0180e404e0, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=吉利德的Veklury现已在美国获批用于COVID-19门诊患者, objectType=article, longId=294611, objectId=7bcb2946115b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bcb2946115b, replyNumber=0, likeNumber=37, createdTime=2022-04-06, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bcb2946115b, moduleTitle=吉利德的Veklury现已在美国获批用于COVID-19门诊患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bcb2946115b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807403, encodeId=c397180e403bc, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=Zepzelca在美国获批，二线治疗转移性小细胞肺癌, objectType=article, longId=195956, objectId=6c89195956f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c89195956f1, replyNumber=0, likeNumber=39, createdTime=2020-12-06, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c89195956f1, moduleTitle=Zepzelca在美国获批，二线治疗转移性小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c89195956f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807399, encodeId=f4e6180e399f8, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗, objectType=article, longId=184092, objectId=92cd1840921e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92cd1840921e, replyNumber=0, likeNumber=29, createdTime=2020-04-26, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92cd1840921e, moduleTitle=默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92cd1840921e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807402, encodeId=97d8180e402e6, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=Rubraca在美国获批，成为获批治疗前列腺癌的PARP抑制剂, objectType=article, longId=194252, objectId=942519425263, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=942519425263, replyNumber=0, likeNumber=31, createdTime=2020-12-04, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=942519425263, moduleTitle=Rubraca在美国获批，成为获批治疗前列腺癌的PARP抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=942519425263)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807401, encodeId=834f180e4014c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=Blueprint的Ayvakit成为美国获批治疗罕见胃肠道间质瘤突变的靶向疗法, objectType=article, longId=186045, objectId=eda21860459a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eda21860459a, replyNumber=0, likeNumber=29, createdTime=2020-12-04, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eda21860459a, moduleTitle=Blueprint的Ayvakit成为美国获批治疗罕见胃肠道间质瘤突变的靶向疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eda21860459a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807400, encodeId=3c32180e400c4, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=阿哌沙班的仿制药在美国获批, objectType=article, longId=185149, objectId=2d0d1851498a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d0d1851498a, replyNumber=0, likeNumber=28, createdTime=2020-03-19, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d0d1851498a, moduleTitle=阿哌沙班的仿制药在美国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d0d1851498a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807398, encodeId=8482180e39829, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=FDA批准韩国SK Life Science的抗癫痫药Xcopri——韩国自主研发在美国获批的化合物, objectType=article, longId=183487, objectId=cbd518348e01, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbd518348e01, replyNumber=0, likeNumber=39, createdTime=2020-04-13, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbd518348e01, moduleTitle=FDA批准韩国SK Life Science的抗癫痫药Xcopri——韩国自主研发在美国获批的化合物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbd518348e01)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807397, encodeId=4ee2180e397a7, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=强生的膀胱癌靶向治疗药物Balversa在美国获批, objectType=article, longId=164357, objectId=a0b416435e0c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0b416435e0c, replyNumber=0, likeNumber=36, createdTime=2019-08-20, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0b416435e0c, moduleTitle=强生的膀胱癌靶向治疗药物Balversa在美国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0b416435e0c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807395, encodeId=13dc180e39569, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤, objectType=article, longId=141927, objectId=83be14192e7c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83be14192e7c, replyNumber=0, likeNumber=24, createdTime=2018-12-24, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83be14192e7c, moduleTitle=Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83be14192e7c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807396, encodeId=c026180e396a8, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=Amicus的Galafold在美国获批, objectType=article, longId=146615, objectId=00741466151d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00741466151d, replyNumber=0, likeNumber=39, createdTime=2018-08-31, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00741466151d, moduleTitle=Amicus的Galafold在美国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00741466151d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807394, encodeId=2281180e39480, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=AZ的Lokelma在美国获批, objectType=article, longId=138787, objectId=0909138e8777, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0909138e8777, replyNumber=0, likeNumber=44, createdTime=2018-10-09, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0909138e8777, moduleTitle=AZ的Lokelma在美国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0909138e8777)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807389, encodeId=a7e6180e389c2, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=Hizentra在美国获批, objectType=article, longId=132934, objectId=6a1213293489, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a1213293489, replyNumber=0, likeNumber=22, createdTime=2018-10-22, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a1213293489, moduleTitle=Hizentra在美国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a1213293489)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807390, encodeId=55d1180e39035, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=Clovis公司的PARP抑制剂美国获批用于复发性卵巢癌的维持治疗, objectType=article, longId=134828, objectId=ba40134828dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba40134828dd, replyNumber=0, likeNumber=24, createdTime=2018-12-27, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba40134828dd, moduleTitle=Clovis公司的PARP抑制剂美国获批用于复发性卵巢癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba40134828dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807392, encodeId=51f7180e3926c, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=GW大麻二酚美国获批又迈进一大步, objectType=article, longId=136023, objectId=83ac13602356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83ac13602356, replyNumber=0, likeNumber=47, createdTime=2018-09-22, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83ac13602356, moduleTitle=GW大麻二酚美国获批又迈进一大步, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83ac13602356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807391, encodeId=9bc3180e39106, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=Shire公司Vonvendi美国获批用于血管性血友病患者的围术期处理, objectType=article, longId=135844, objectId=96b4135844e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96b4135844e7, replyNumber=0, likeNumber=28, createdTime=2018-11-11, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96b4135844e7, moduleTitle=Shire公司Vonvendi美国获批用于血管性血友病患者的围术期处理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96b4135844e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807393, encodeId=15c4180e393a3, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=AZ的Tagrisso作为肺癌一线用药在美国获批, objectType=article, longId=136059, objectId=719a136059b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=719a136059b9, replyNumber=0, likeNumber=31, createdTime=2018-06-03, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=719a136059b9, moduleTitle=AZ的Tagrisso作为肺癌一线用药在美国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=719a136059b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807388, encodeId=424d180e38831, content=<a href='/topic/show?id=bbbfe98944d' target=_blank style='color:#2F92EE;'>#美国获批#</a>, objectTitle=治疗失明的基因疗法有望首次在美国获批, objectType=article, longId=117672, objectId=016911e67292, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=016911e67292, replyNumber=0, likeNumber=32, createdTime=2018-09-02, rootId=0, userName=lq1767, userId=19ad38, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=016911e67292, moduleTitle=治疗失明的基因疗法有望首次在美国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=016911e67292)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

美国获批

2020-05-29

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

阿斯利康和第一三共制药的Enhertu在美国获批用于早期治疗乳腺癌

2022-10-26

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

吉利德的Veklury现已在美国获批用于COVID-19门诊患者

2022-04-06

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

Zepzelca在美国获批，二线治疗转移性小细胞肺癌

2020-12-06

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗

2020-04-26

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

Rubraca在美国获批，成为获批治疗前列腺癌的PARP抑制剂

2020-12-04

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

Blueprint的Ayvakit成为美国获批治疗罕见胃肠道间质瘤突变的靶向疗法

2020-12-04

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

阿哌沙班的仿制药在美国获批

2020-03-19

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

FDA批准韩国SK Life Science的抗癫痫药Xcopri——韩国自主研发在美国获批的化合物

2020-04-13

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

强生的膀胱癌靶向治疗药物Balversa在美国获批

2019-08-20

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

Braftovi/Mektovi联合在美国获批用于BRAF突变转移性黑素瘤

2018-12-24

智者为医08 (审核中...)

前往app查看评论内容

#美国获批#

Amicus的Galafold在美国获批

2018-08-31

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

AZ的Lokelma在美国获批

2018-10-09

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

Hizentra在美国获批

2018-10-22

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

Clovis公司的PARP抑制剂美国获批用于复发性卵巢癌的维持治疗

2018-12-27

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

GW大麻二酚美国获批又迈进一大步

2018-09-22

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

Shire公司Vonvendi美国获批用于血管性血友病患者的围术期处理

2018-11-11

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

AZ的Tagrisso作为肺癌一线用药在美国获批

2018-06-03

lq1767 (审核中...)

前往app查看评论内容

#美国获批#

治疗失明的基因疗法有望首次在美国获批

2018-09-02

科室
- - 订阅+
  - 更多科室
工具
服务